Colon cancer
Drug research and approvals for colon cancer: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 1,194 studies of colon cancer are recruiting on ClinicalTrials.gov, Health Canada has authorized 7 drug trials for it since 2013, and the EU has 5 authorised medicines for it.
- Recruiting worldwide: 1,194
- Trials authorized in Canada: 7
- FDA orphan approvals: 0
- EU medicines: 5
Recruiting Now
Newest start dates first, of 1,194 recruiting on ClinicalTrials.gov ↗- Testing the Combination of Anti-Cancer Drugs, Botensilimab (AGEN1181) and Balstilimab (AGEN2034), After Standard…NCT07551596 · Phase 2 · National Cancer Institute (NCI) · starts May 25, 2027
- A Bowel Management Program (Retrograde Rectal Enema) for the Treatment of Low Anterior Resection Syndrome in Rectal…NCT06424522 · Not applicable · Ohio State University Comprehensive Cancer Center · starts Feb 15, 2027
- Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or…NCT07271355 · Phase 3 · City of Hope Medical Center · starts Jan 4, 2027
- Gemcitabine, Cisplatin, Nab-paclitaxel (GAP) and Cemiplimab for Locally Advanced Biliary Tract Cancer (BTC)NCT07433673 · Phase 2 · Columbia University · starts Jan 1, 2027
- Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal…NCT07750158 · Phase 3 · Exelixis · starts Dec 18, 2026
- Testing the Effects of Exercise on Colorectal Cancer Development After Treatment With Pelvic Radiation Therapy for…NCT07790718 · Not applicable · City of Hope Medical Center · starts Dec 16, 2026
- SumMET: Study of [225Ac]Ac-FL-261 in Participants With Solid Tumors Overexpressing c-METNCT07873450 · Phase 1 / Phase 2 · Full-Life Technologies UK Limited · starts Dec 1, 2026
- Novel Couple-Based Mindfulness Intervention for Metastatic Colorectal CancerNCT07759921 · Not applicable · University of Colorado, Denver · starts Dec 1, 2026
- TCR1188-ABC Cells in KRAS-mutated CancersNCT07594067 · Phase 1 · University of Pennsylvania · starts Dec 1, 2026
- Neoadjuvant Pembrolizumab and Porustobart in Resectable pMMR/MSS Colon CancerNCT07808151 · Phase 2 · Solstice Oncology, Inc. · starts Nov 30, 2026
Trials Authorized in Canada
Newest first; search them all in Canada trials| May 31, 2023 | A phase 3, open-label, randomized study of perioperative dostarlimab monotherapy versus standard of care in participants with untreated t4n0 or stage iii…JEMPERLI | GSK | Ongoing |
| May 3, 2023 | Colon adjuvant chemotherapy based on evaluation of residual disease (circulate-us)IRINOTECAN | CANADIAN CANCER TRIALS GROUP, CANCER RESEARCH INSTITUTE, QUEEN'S UNIVERSITY | Ongoing |
| Dec 22, 2020 | Circulating tumor dna analysis informing adjuvant chemotherapy in stage iii colon cancer: a multicentre phase II/iii randomised controlled study (dynamic iii)IRINOTECAN | CANADIAN CANCER TRIALS GROUP, CANCER RESEARCH INSTITUTE, QUEEN'S UNIVERSITY | Ongoing |
| Apr 1, 2020 | Phase II/iii study of circulating tumor dna as a predictive marker for response to adjuvant chemotherapy in patients with stage ii colon cancerOXALIPLATIN | CANADIAN CANCER TRIALS GROUP, CANCER RESEARCH INSTITUTE, QUEEN'S UNIVERSITY | Ongoing |
| Jan 8, 2019 | Lymphatic mapping for colon cancer using indocyanine green fluorescence imagingINDOCYANINE GREEN | MCGILL UNIVERSITY HEALTH CENTRE | Pending |
| May 2, 2017 | A phase III, randomised, international trial comparing mfolfirinox triplet chemotherapy to mfolfox for high-risk stage iii colon cancer in adjuvant settingIRINOTECAN | CANADIAN CANCER TRIALS GROUP, CANCER RESEARCH INSTITUTE, QUEEN'S UNIVERSITY | Ongoing |
| Mar 24, 2014 | A phase 2 clinical trial of nivolumab and nivolumab plus ipilimumab in recurrent and metastatic microsatellite high (msi-h) colon cancer (checkmate 142:…NIVOLUMAB / IPILIMUMAB / [18F]-FLUORODEOXYGLUCOSE | Bristol-Myers Squibb | Ongoing |
Medicines Authorised in the EU
Newest first| Nov 19, 2012 | Capecitabine Medaccapecitabine · generic | medac Gesellschaft für klinische Spezialpräparate mbH | EMA ↗ |
| Apr 20, 2012 | Capecitabine Tevacapecitabine · generic | Teva Pharma B.V. | EMA ↗ |
| Apr 20, 2012 | Ecansya (previously Capecitabine Krka)capecitabine · generic | KRKA tovarna zdravil d.d. Novo mesto | EMA ↗ |
| Apr 20, 2012 | Capecitabine Accordcapecitabine · generic | Accord Healthcare S.L.U. | EMA ↗ |
| Feb 2, 2001 | Xelodacapecitabine | CHEPLAPHARM Arzneimittel GmbH | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA